$599

Gubra Q2 ‘25 Earnings; Advances New Obesity Asset

Gubra hosted its Q2 ‘25 earnings call and provided updates to its obesity pipeline (view press release; view slides). Of note, the company plans to initiate a Ph1 study of its lean mass-sparing obesity candidate, GUB-UCN2, in early 2026. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here